Literature DB >> 32510495

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection.

Sameera Vipat1, Greg Brennan1, Chorong Park1, Sherry L Haller2, Stefan Rothenburg3.   

Abstract

Vaccinia virus (VACV) was instrumental in eradicating variola virus (VARV), the causative agent of smallpox, from nature. Since its first use as a vaccine, VACV has been developed as a vector for therapeutic vaccines and as an oncolytic virus. These applications take advantage of VACV's easily manipulated genome and broad host range as an outstanding platform to generate recombinant viruses with a variety of therapeutic applications. Several methods have been developed to generate recombinant VACV, including marker selection methods and transient dominant selection. Here, we present a refinement of a host range selection method coupled with visual identification of recombinant viruses. Our method takes advantage of selective pressure generated by the host antiviral protein kinase R (PKR) coupled with a fluorescent fusion gene expressing mCherry-tagged E3L, one of two VACV PKR antagonists. The cassette, including the gene of interest and the mCherry-E3L fusion is flanked by sequences derived from the VACV genome. Between the gene of interest and mCherry-E3L is a smaller region that is identical to the first ~150 nucleotides of the 3' arm, to promote homologous recombination and loss of the mCherry-E3L gene after selection. We demonstrate that this method permits efficient, seamless generation of rVACV in a variety of cell types without requiring drug selection or extensive screening for mutant viruses.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32510495      PMCID: PMC8051324          DOI: 10.3791/61049

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  31 in total

1.  Compact, synthetic, vaccinia virus early/late promoter for protein expression.

Authors:  S Chakrabarti; J R Sisler; B Moss
Journal:  Biotechniques       Date:  1997-12       Impact factor: 1.993

2.  The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur.

Authors:  P P Pastoret; B Brochier
Journal:  Epidemiol Infect       Date:  1996-06       Impact factor: 2.451

3.  Molecular genetics of vaccinia virus: demonstration of marker rescue.

Authors:  E Nakano; D Panicali; E Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

4.  The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase.

Authors:  H W Chang; J C Watson; B L Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

Review 5.  Construction and isolation of recombinant MVA.

Authors:  Caroline Staib; Ingo Drexler; Gerd Sutter
Journal:  Methods Mol Biol       Date:  2004

6.  Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection.

Authors:  Giulia Di Lullo; Elisa Soprana; Maddalena Panigada; Alessio Palini; Volker Erfle; Caroline Staib; Gerd Sutter; Antonio G Siccardi
Journal:  J Virol Methods       Date:  2008-12-10       Impact factor: 2.014

7.  Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice.

Authors:  Duong H Nguyen; Nanhai G Chen; Qian Zhang; Ha T Le; Richard J Aguilar; Yong A Yu; Joseph Cappello; Aladar A Szalay
Journal:  Mol Ther       Date:  2013-06-14       Impact factor: 11.454

Review 8.  Poxviruses as vaccine vectors.

Authors:  P-P Pastoret; A Vanderplasschen
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2003-10       Impact factor: 2.268

9.  A survey of host range genes in poxvirus genomes.

Authors:  Kirsten A Bratke; Aoife McLysaght; Stefan Rothenburg
Journal:  Infect Genet Evol       Date:  2012-12-23       Impact factor: 3.342

10.  Myxoma virus protein M029 is a dual function immunomodulator that inhibits PKR and also conscripts RHA/DHX9 to promote expanded host tropism and viral replication.

Authors:  Masmudur M Rahman; Jia Liu; Winnie M Chan; Stefan Rothenburg; Grant McFadden
Journal:  PLoS Pathog       Date:  2013-07-04       Impact factor: 6.823

View more
  4 in total

1.  Species-specific inhibition of antiviral protein kinase R by capripoxviruses and vaccinia virus.

Authors:  Chorong Park; Chen Peng; Greg Brennan; Stefan Rothenburg
Journal:  Ann N Y Acad Sci       Date:  2019-01-15       Impact factor: 5.691

2.  Orthopoxvirus K3 orthologs show virus- and host-specific inhibition of the antiviral protein kinase PKR.

Authors:  Chorong Park; Chen Peng; M Julhasur Rahman; Sherry L Haller; Loubna Tazi; Greg Brennan; Stefan Rothenburg
Journal:  PLoS Pathog       Date:  2021-01-14       Impact factor: 6.823

3.  Crocodilepox Virus Protein 157 Is an Independently Evolved Inhibitor of Protein Kinase R.

Authors:  M Julhasur Rahman; Loubna Tazi; Sherry L Haller; Stefan Rothenburg
Journal:  Viruses       Date:  2022-07-19       Impact factor: 5.818

4.  Ancient Gene Capture and Recent Gene Loss Shape the Evolution of Orthopoxvirus-Host Interaction Genes.

Authors:  Tatiana G Senkevich; Natalya Yutin; Yuri I Wolf; Eugene V Koonin; Bernard Moss
Journal:  mBio       Date:  2021-07-13       Impact factor: 7.867

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.